Drug Profile
Polysaccharide peptide
Latest Information Update: 17 Oct 2021
Price :
$50
*
At a glance
- Originator Unknown
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Jul 1998 Profile reviewed
- 14 Jul 1998 No-Development-Reported for Cancer in Hong Kong (Unknown route)
- 16 Jun 1995 Preclinical development for Cancer in Hong Kong (Unknown route)